Clinical Trial

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Study acronym: ROTOR
Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to describe the epidemiology, treatment pathway, treatment access, wastage of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), and health care resource use among adults with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer (BC) in England, including their treatment pathway leading to progression to metastatic BC for those who were initially diagnosed with early BC. This was a retrospective cohort study using linked registry and administrative data.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-23.
Trial Details
NCT Number NCT07498413
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Cancer
Enrollment 218,677 participants
Start Date 2023-06-08
Primary Completion 2025-07-18 (estimated)
Study Completion 2025-07-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-01